EFFECTS OF PULMONARY REHABILITATION ON MARKERS OF SYSTEMIC INFLAMMATION AND SERUM TESTOSTERONE LEVEL IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Summary. COPD affects not only the respiratory system but has systemic effects including peripheral muscle dysfunction, synovial and vascular pathology and depression partly caused by the direct influence of inflammatory mediators. Pulmonary rehabilitation is recognized as a crucial component of management of patients with COPD. This study was performed in Research Institute of Pulmonology of Federal Medical and Biological Agency and evaluated one of rehabilitation methods, namely physical training, in term of its influence on systemic inflammation markers and level of testosterone in COPD patients. The study involved 31 patients with COPD stage III–IV treated with standard drug therapy according to the disease severity. Of them, 16 patients were involved in pulmonary rehabilitation programs. As a result, pulmonary rehabilitation group patients improved 6-min distance by 80 m, FEV1 by 13 % and decreased FRV by 14 % and RV by 30 % from baseline. These parameters did not change or changed non-significantly in patients treated with medications alone. Systemic inflammation and testosterone level were also improved in pulmonary rehabilitation group.

1. Bourdin A., Burgel P.-R., Chanez P. et al. Recent advances in COPD: pathophysiology, respiratory physiology and clinical aspects, including comorbidities. Eur. Respir. Rev. 2009; 18:198–212.

2. Watz H., Waschki B., Boehme C. et al. Extrapulmonary effects of chronic obstructive disease on physical activity. Am. J. Respir. Crit. Care Med. 2007: 200707–201011OC,doi: 10.1164.

3. Buck M., Chojkier M. Muscle wasting and dedifferentiation induced by oxidative stress in a murine model of cachexia is prevented by inhibitors of nitric oxide synthesis and antioxidants. EMBO J. 1996; 15: 1753–1765.

4. Janssen S., Gayan-Ramirez G., Reynders V. et al. IL-6 cause respiratory and peripheral muscles atropy in rats. Eur.Respir. J. 2003; 22 (Suppl. 45): 573s.

5. Haddad F., Zaldivar F., Cooper D.M., Adams G.R. IL-6-induced skeletal muscle atrophy. J. Appl. Physiol. 2005; 98:911–917.

6. Creutzberg E.C., Schols A.M., Weling-Scheepers C.A. et al.Characterization of nonresponse to high caloric oral nutritional therapy in depleted patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2000;161: 745–752.

7. Eid A.A., Ionescu A.A., Nixon L.S. et al. Inflammatory response and body composition in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2001; 164:1414–1418.

8. Godoy I., Campana A.O., Geraldo R.R. et al. Cytokines and dietary energy restriction in stable chronic obstructive pulmonary disease patients. Eur. Respir. J. 2003; 22: 920–925.

9. Malo O., Sauleda J., Busguets X. et al. Systemic inflammation during exacerbations of hronic obstructive pulmonary disease. Arch. Bronconeumol. 2002; 38: 172–176.

10. Debigare R., Marguis K., Cote C.H. et al. Catabolic / anabolic balance and muscle wasting in patients with COPD.Chest 2003; 124: 83–89.

11. Brodsky I.G., Balagopal P., Nair K.S. Effects of testosterone replacement on muscle mass and muscle protein synthesis in hypogonadal men – a clinical research center study.J. Clin. Endocrinol. 1996; 81: 3469–3475.

12. Ferrando A.A., Tipton K.D., Doyle D. et al. Testosterone injection stimulates net protein synthesis but not tissue amino acid transport. Am. J. Physiol. 1998; 275:E864–E871.

13. Gambera A., Scagliola P., Falsetti L., Bianchi U. Androgens, insulin-like growth factor-I (IGF-I), and carrier proteins(SHBG, IGFBP 3) in postmenopause. Menopause 2004;11: 159–166.

14. Muller M., den Tonkelaar I., Thijssen J.H. et al. Endogenous sex hormones in men aged 40–80 years. Eur. J. Endocrinol.2003; 149: 583–589.

15. Semple P.D., Beastall G.H., Watson W.S., Hume R. Serum testosterone depression associated with hypoxia in respiratory failure. Clin. Sci. (Lond.) 1980; 58: 105–106.

16. Casaburi R., Goren S., Bhasin S. Substantial prevalence of low anabolic hormone levels in COPD undergoing rehabilitation. Am. J. Respir. Crit. Care Med. 1996; 153: A 128.

17. Global initiative for chronic obstructive lung disease. Pocket guide to COPD. Diagnosis, management, and prevention.Medical Communications Resources, Inc.; 2008.

18. Shel A.W., Derchak P.A., Pegelow D.F., Dempsey J.A.Threshold effects of respiratory muscle work on limb vascular resistance. Am. J. Physiol. Heart Cire. Physiol. 2002;282: H1732–H1738.

19. Sala E., Roca J., Marrades R.M. et al. Effects of endurance training on skeletal muscle bioenergetics in chronic obstructive pulmonary disease. Am. J. Respir. Crit Care Med. 1999;159: 1726–1734.

20. Green R.H., Singh S.J., Williams J., Morgan M.D. A randomized controlled trial of four weeks versus seven weeks of pulmonary rehabilitation in chronic obstructive pulmonary disease. Thorax 2001; 56: 143–145.

21. Plankeel J.F., McMullen B., MacIntyre N.R. Exercise out comes after pulmonary rehabilitation depend on the initial mechanisms of exercise limitation among non-oxygen-dependent COPD patients. Chest 2005; 127: 110–116.

22. Гриппи М.А. Патофизиология легких. М.:БИНОМ;СПб.: Невский диалект; 1999. 267–271, 284.

23. ATS statement: guidelines for the six minute walk test. Am.J. Respir. Crit. Care Med. 2002; 166: 111–117.

24. Lotters F., van Tol B., Kwakkel G., Gosselink R. Effects of controlled inspiratory muscle training in patients with COPD: a meta-analysis. Eur. Respir. J. 2002; 20: 570–577.

25. McConnell A.K., Romer L.M., Weiner P. Inspiratory muscle training improver lung function and exercise capacity in adults with cystic fibrosis. Chest 2004; 126: 405–411.

26. Wanger J., Clausen J.L., Coates A. et al. Standardisation of the measurement of lung volumes. Eur. Respir. J. 2005; 26:511–522.

27. Romer L.M., McConnell A.K. Specificity and reversibility of inspiratory muscle training. Med. Sci. Sports Exerc. 2003;35: 237–244.

28. Lisboa C., Villafranca C., Leiva A. et al. Inspiratory muscle training in chronic airflow limitation: effect on exercise performance. Eur. Respir. J. 1997; 10: 537–542.